O'Meara Maeve
SEC CIK 1742487 · EDGAR
Companies
| Ticker | Company | Title | Holding | Bought | Sold | Trades | First | Last |
|---|---|---|---|---|---|---|---|---|
| STLN | Starling Oncology, Inc. | Dir | 109.1K | — | — | 4 | 2022-03-21 | 2023-12-26 |
Most active insiders at STLN, 12 months
| # | Insider | Title | Bought | Sold |
|---|---|---|---|---|
| 1 | Chernett Jorey | 10% | $2.69M | — |
| 2 | Hively Brad | Dir | — | $2.00M |
| 3 | Kaushal Mohit | Dir | — | $335.1K |
| 4 | Podnos Yale | Chief Medical Off | — | $276.4K |
| 5 | Pacala Mark L | Dir | — | $200.0K |
| 6 | Carter Robert Ross | CFO | — | $879.32 |
| 7 | England Kristin | Chief Administrative Off | — | — |
| 8 | Langsam Jeffrey | Chief Clinical Off | — | — |
| 9 | Ling Gabriel | Dir | — | — |
| 10 | TOI M, LLC | Dir | — | — |
O'Meara Maeve made no open-market trades at STLN in the last 12 months.
Transactions 4
| X | Filed | Traded | Ticker | Company | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2023-12-28 | 2023-12-26 | STLN | Starling Oncology, Inc. | O'Meara Maeve | Dir | A - Grant | $0.00 | +50.0K | 109.1K | +85% | $0 | |
| 2023-03-21 | 2023-03-17 | STLN | Starling Oncology, Inc. | O'Meara Maeve | Dir | A - Grant | $0.00 | +16.4K | 59.1K | +38% | $0 | |
| 2022-11-21 | 2022-11-17 | STLN | Starling Oncology, Inc. | O'Meara Maeve | Dir | A - Grant | $0.00 | +22.7K | 42.7K | +114% | $0 | |
| M | 2022-03-23 | 2022-03-21 | STLN | Starling Oncology, Inc. | O'Meara Maeve | Dir | A - Grant | $0.00 | +20.0K | 20.0K | New | $0 |
Purchase Sale Sale after option exercise All abbreviations